- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00181571
A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Concerta was specially developed to replace three-times-a-day IR methylphenidate, making it an ideal option for patients with ADHD. Moreover, the once-a-day administration of Concerta secures a steady delivery of methylphenidate across the day, minimizing the well-known risks of peaks and valleys of IR methylphenidate, which could offer an added advantage to the pharmacokinetic advantage of once-a-day administration. Despite these putative advantages, whether this new delivery system will lead to the same results as those documented with immediate-response methylphenidate in the treatments of adults with ADHD requires empirical corroboration. To this end we are conducting a randomized controlled clinical trial to evaluate the short- and medium-term safety and efficacy of Concerta in the treatment of adults with ADHD with and without co-morbid psychiatric disorders. We also wish to examine the role of genetics in predicting ADHD treatment response to Concerta. There is growing literature that supports the role of genetic factors in treatment response in youth with ADHD, and we seek to further explore this relationship in adults.
The proposed study includes the use of a 34-week design to document the response rate, assessment of the impact of Concerta on functional capacities (quality of life, psychosocial function) and cognition, and careful assessment of safety and tolerability.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Cambridge, Massachusetts, United States, 02138
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female outpatients older than 18 and younger than 55 years of age.
- Subjects with the diagnosis of attention deficit hyperactivity disorder (ADHD), by DSM-IV, as manifested in clinical evaluation and confirmed by structured interview.
- ADHD Symptom Checklist score > 24.
- Patients with past history of depression, bipolar disorder, anxiety disorder (including OCD) without current disorder for > 3 months as ascertained through structured diagnostic interview and clinical exam.
- Subjects treated for anxiety disorders and depression who are on a stable medication regimen for at least three months, and who have a disorder-specific CGI-Severity score ≤ 3 (mildly ill) and who have a score on the Hamilton-Depression and Hamilton-Anxiety rating scales below 15 (mild range).
- Subjects with a past history of tics but tic free for > 1 year.
- Subjects with past history of substance use disorders but substance free for > 6 months.
- Subjects receiving non-MAOI antidepressants (e.g., SSRI's, bupropion, venlafaxine) or benzodiazepines who have been on a stable regimen for > 3 months for any of the conditions listed above.
Exclusion Criteria:
- Any clinically unstable psychiatric conditions including the following: acute psychosis, acute panic, acute OCD, acute mania, acute suicidality, bipolar disorder, acute substance use disorders (alcohol or drugs, sociopathy, criminality, or delinquency.
- Any metabolic, neurological, hepatic, renal, cardiovascular, hematological, opthalmic, or endocrine disease.
Clinically significant abnormal baseline laboratory values which include the following:
- Values > 20% above the upper range of the laboratory standard of a basic metabolic screen.
- Exclusionary blood pressure > 140 (systolic) and 90 (diastolic).
- Exclusionary ECG parameters: QTC > 460 msec, QRS > 120 msec, and PR > 200 msec. Subjects having ECG evidence of ischemia or arrhythmia as reviewed by an independent cardiologist.
- Mental retardation (IQ <75).
- Organic brain disorders.
- Seizures or tics in the last year.
- Pregnant or nursing females.
- Subjects with current adequate treatment for ADHD or a history of a previous adequate trial of Concerta.
Non-English speaking subjects will not be allowed into the study for the following reasons:
- the assessment instruments are unavailable and have not been adequately standardized in other languages;
- our clinical trials facility is located in Cambridge and not at the MGH main campus; thus translators are unavailable;
- even if such translation services were available, the assessments in the English language conducted by English-speaking clinicians and raters with English-speaking subjects are already extremely time-consuming, lasting many hours, making it unfeasible, unrealistic, and of dubious clinical validity to conduct them with a translator with non-English-speaking subjects;
- psychiatric questionnaires and evaluations are taxing, and adding the complexity of a translator has the potential to make the patient experience even more exhausting
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 2
Placebo
|
up to a maximum dose of 1.3 mg Placebo /kg/day, and not more than 144 mg/day for any subject regardless of weight.
|
Active Comparator: 1
Concerta
|
up to a maximum dose of 1.3 mg Concerta/kg/day, and not more than 144 mg/day for any subject regardless of weight.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Symptom reduction using ADHD-Clinical Global Impression and ADHD Symptom Checklist Severity scale administered at each visit.
Time Frame: 34 weeks
|
34 weeks
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Attention Deficit and Disruptive Behavior Disorders
- Neurodevelopmental Disorders
- Attention Deficit Disorder with Hyperactivity
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Methylphenidate
Other Study ID Numbers
- 2003-p-000037
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ADHD
-
The Hong Kong Polytechnic UniversityRecruiting
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)Recruiting
-
VIZO Specs LtdRecruiting
-
Loewenstein HospitalWingate InstituteRecruiting
-
Florida State UniversityRecruiting
-
Florida International UniversityRecruiting
-
Region Örebro CountyRecruiting
-
Johns Hopkins UniversityWithdrawn
-
Tris Pharma, Inc.Premier Research Group plcCompleted
Clinical Trials on methylphenidate HCl (Concerta)
-
Ortho-McNeil Janssen Scientific Affairs, LLCCompletedAttention Deficit Hyperactivity DisorderUnited States
-
Massachusetts General HospitalOrtho-McNeil Janssen Scientific Affairs, LLCCompleted
-
University of PittsburghOrtho-McNeil Janssen Scientific Affairs, LLCWithdrawnAttention-Deficit/Hyperactivity Disorder (ADHD)United States
-
Purdue Pharma LPTerminatedAttention-Deficit/Hyperactivity DisorderUnited States
-
Massachusetts General HospitalMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.CompletedBipolar Disorder | ADHDUnited States
-
Noven TherapeuticsNoven Pharmaceuticals, Inc.CompletedAttention Deficit Disorder With Hyperactivity
-
Noven TherapeuticsCompletedAttention Deficit Hyperactivity Disorder
-
Ortho-McNeil Janssen Scientific Affairs, LLCCompleted
-
Janssen Korea, Ltd., KoreaCompletedAttention Deficit Disorder With Hyperactivity
-
Bundang CHA HospitalHallym University Medical CenterCompletedAttention Deficit Hyperactivity DisorderKorea, Republic of